Royal Bank of Canada’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Royal Bank of Canada’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-13	Closed	–	–	6618
2013 Q3	$0	Sell	13 -37	-74%	-$1.69K	﹤0.01%	6563
2013 Q2	$2K	Buy	+50	New	+$2.27K	﹤0.01%	5680

Other funds holding KBIO

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

LBH

Lehman Brothers Holdings New York $794K AUM 28.79% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Royal Bank of Canada's KBIO Position: Q4 2013 in Review

Royal Bank of Canada sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2013, closing a stake of 13 shares.

Royal Bank of Canada first reported a position in KBIO in Q2 2013 and held it in 2 quarters. The position peaked at $2K in Q2 2013. 46 funds tracked by Wall St. Rank hold KBIO as of Q4 2013.

Royal Bank of Canada reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2013 after selling out during the quarter.
Royal Bank of Canada sold 13 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2013.
Royal Bank of Canada first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 2 quarters.
Royal Bank of Canada's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $2K in Q2 2013.
46 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2013.

Based on Royal Bank of Canada's 13F filing for Q4 2013, filed 14 Feb 2014.